News Center

• DCP Capital Closes Their Debut PE Fund with US$2.5 Billion of Total Commitments

  Beijing, Hong Kong – April 16, 2019 – DCP Capital (“DCP”), a leading international private equity investment firm, today announced the final closing of the firm’s first Greater China focused US dollar private equity fund, DCP Capital Partners I (the “Fund”), which closed at its cap of over US$2 billion in commitments.

  2019-04-16

• Ex-KKR China Heads Said to Raise $2 Billion for New Fund

  KKR & Co.’s former China heads have raised $2 billion for their debut private equity fund, according to people familiar with the matter. DCP Capital has committed 30 percent of the money for six deals in China, and the firm has also raised $500 million for a fund denominated in yuan that focuses on domestic Chinese investments.

  2019-04-16

• David Liu: Hailed by Wu Shangzhi as "the most astute PE investor in China"

  KKR made an announcement that shocked the market yesterday. It said that David Liu, partner at KKR, Co-head of KKR Asia Private Equity, and CEO of KKR Greater China, has resigned. Together with another partner, Julian Wolhardt, the two will set up their own private equity firm.

  2016-08-31

• DCP Completes Strategic Investment in Datong, Becoming Its Largest Institutional Shareholder

  (November 29, 2021) DCP announced the completion of a strategic investment in Datong and has become the Company’s largest institutional shareholder. DCP indicated that it will work closely with Datong’s management team to create a new insurance ecosystem driven by product customization, demand matching, and a comprehensive service matrix to provide professional insurance services to Chinese consumers.

  2021-11-29

• DCP Completes Investment in Valgen Medtech, Another Landmark Investment in the Interventional Structural Heart Disease Treatment in China

  DCP announced the completion of a B round investment of multi-hundred million dollars in Hangzhou Valgen Medtech Co., Ltd. ("Valgen" or the “Company”), a leading innovator in the treatment of structural heart disease. The Company was incubated by DiNova Medtech (“DiNova”). The proceeds will be used to accelerate research and development in the treatment of mitral and tricuspid valve diseases.

  2021-05-07

• DCP Completes Investment in Adopt A Cow, Backing a Leader in China’s Consumption Upgrade Megatrend

  DCP announced the completion of its investment in Adopt A Cow Dairy Co., Ltd. ("Adopt A Cow" or the “Company”), a rapidly growing dairy product company in China with a Direct-To-Customer (DTC) approach. The Company will use the proceeds from investment to build best-in-class dairy farms and processing facilities, introduce high-grade Australian dairy cow breed and upgrade its supply chain to ensure the safety and high quality of its products.

  2021-04-19

• DCP Portfolio Company Tonghua Dongbao Announced a Product In-license Deal and Diabetic Strategic Partnership with WuXi AppTec

  (Shanghai,March 11th,2021) Tonghua Dongbao Pharmaceutical Co., Ltd. (“Dongbao”), a portfolio company of DCP and a leading pharmaceutical company in China focused on diabetes treatment, announced a product in-license deal with Wuxi AppTec Co., Ltd. (“Wuxi AppTec”), a global leading R&D service provider in pharmaceutical, biotech and medical device industries.

  2021-04-01

• DCP Completes Strategic Investment in Hotwon Group

  DCP announced that it has co-led with CPE a US$300 million equity investment round in Hotwon Group . The investment will fund Hotwon’s robust data center pipeline to further capitalize on the rapid development of China's data center industry.

  2020-12-15

• DCP Announces Strategic Investment in Tonghua Dongbao, A Leading Diabetes Pharmaceutical Company in China

  DCP, a leading international private equity firm, announced that it has reached an agreement to acquire a 9% stake in A-share listed Tonghua Dongbao Pharmaceutical Co., Ltd. from Dongbao Industrial Group Limited, for a consideration of approximately US$283 million.

  2020-09-10

• Venus Medtech Forms Healthcare Investment Platform with DCP Capital, Qiming Venture Partners to Invest in Innovative Medical Device Companies

  Venus Medtech (Hangzhou) Inc. , DCP Capital and Qiming Venture Partners today jointly announced the completion of a definitive agreement to form Ascendum Capital Partners . Ascendum is dedicated to investing in innovative medical device companies in the global cardiovascular and lung disease treatment space. By leveraging Venus’s industry resources and the investment expertise of DCP Capital and Qiming Venture Partners, Ascendum aims to accelerate the R&D and commercialization of global leading

  2020-07-16

• DCP Capital Completes Investment in MFS Technology

  DCP Capital (“DCP”) today announced the completion of its investment in MFS Technology . DCP acquired a controlling stake in MFS in partnership with the Company’s senior management team, who invested significantly alongside DCP. MFS designs, prototypes, and manufactures custom-designed flexible printed circuit boards and rigid printed circuit boards used in electronic devices and equipment for leading global companies.

  2019-12-26

• DCP Capital Completed Equity Investment in COFCO Meat

  DCP Capital announced the completion of an equity investment in COFCO Meat Holdings Limited. Through this investment, DCP strengthened its strategic cooperation with COFCO Meat to continue building and upgrading the Company’s large-scale, modernized hog farms and meat processing facilities to meet the increasing demand for quality pork products in China.

  2019-07-30

• DCP Capital invests $120m in Sunpower Group

  DCP Capital, a private equity firm focusing on China, on Tuesday announced investment of $120 million through two rounds of convertible bonds to fuel the further growth of Sunpower Group Limited.

  2018-09-12

• DCP’s Investment in Sunpower Group

  DCP Capital (“DCP”) today announced that it has invested a total of USD$120 million through 2 rounds of Convertible Bonds to support the continued growth of Sunpower Group Limited (“Sunpower” or the “Company”) (SGX: 5GD.SI).

  2018-09-11

• DCP Capital Announces Equity Investment in Venus Medtech

  DCP Capital (“DCP”) announced that it has reached a definitive agreement with Venus Medtech for an equity investment. The investment will facilitate Venus Medtech’s buildout of its sales network to establish the leading position in China’s transcatheter aortic valve replacement (TAVR) market.

  2018-05-16